13:45
14:30
Session Chair
Prof. Tihomir TOMASIC
UNIVERSITY OF LJUBLJANA, Ljubljana, Slovenia
14:35
KL01 - From Hits, to Leads to Chemical Probes: An Exciting Journey
Prof. Cristina NEVADO
UNIVERSITY OF ZURICH, Zurich, Switzerland
Cristina Nevado graduated in chemistry at the Autónoma University of Madrid in 2000. In October 2004 she received her PhD in organic chemistry from the same University working with Prof. Antonio M. Echavarren in late transition metal catalyzed reactions. After a post-doctoral stay in the group of Prof. Alois Fürstner at the Max-Planck-Institut für Kohlenforschung (Germany), she joined the University of Zürich as an Assistant Professor in May 2007. In 2011, Cristina was awarded the Chemical Society Reviews Emerging Investigator Award and the Thieme Chemistry Journal Award in recognition of her contributions in the field of synthetic organic chemistry. In 2012 she received an ERC Junior Investigator grant and has been awarded the Werner Prize of the Swiss Chemical Society. In 2013 she became Full Professor at the Organic Chemistry Institute of the University of Zürich. Rooted in the wide area of organic chemistry, her research program is focused on complex chemical synthesis and new organometallic reactions.
YMCS competition presentation session I
Session Chair
Dr Daniel MERK
ETH ZÜRICH, Zürich, Switzerland
15:05
OC01 - Impact and Prediction of Binding Kinetics on in Vivo Drug Efficacy
Winner of the young medicinal chemist meeting in France
Dr Abdennour BRAKA
IRIM, Gif-sur-Yvette, France
BIOGRAPHICAL SKETCH
Born: May 26, 1987 Citizenship: French
Post-doc in Drug design, biochemistry and enzymology
Institut de recherche en infectiologie de Montpellier - IRIM - CNRS Montpellier - France
EDUCATION
- Ph.D., molecular modeling and drug design, 2018, University of Orléans, France, Highest honors
- Master in Drug Design, 2014, University of Caen – Basse Normandie, France - Faculty of Pharmacy (Rank 1/12) , Highest honors
- Doctorate in pharmacy , 2011, University of Batna, Algeria - Faculty of Pharmacy
- Bachelor's degree, honors, 2006
APPOINTMENTS
- April 2018 to present: Post-doc in Drug design, biochemistry and enzymology
Laboratory: Institut de recherche en infectiologie de Montpellier - IRIM - CNRS Montpellier - France.
“Design and optimize lead compounds targeting an ectoenzyme involved in the anticancer immune response”
- Oct 2014 – March 2018: Thesis in molecular modeling and drug design
“Binding kinetics prediction of protein kinase inhibitors and their affinity by flexible docking”
Laboratores:
Institut de Chimie Organique et Analytique – ICOA, Orléans, France
Centre de biophysique moléculaire - CBM, Orléans, France
- 2014 : Master 2 Internship
“Design of new multi-target ligands by molecular modeling: application to Alzheimer's disease”
Laboratory: Centre d’Études et de Recherche sur le Médicament de Normandie (CERMN), France
- 2013 : Master 1 Internship
“Pharmacophore modeling and virtual screening of CERMN’s chemical library applied to human Urotensin-II”
Laboratory: CERMN, France
15:25
OC02 - Prospective Applications of Artificial Intelligence in de Novo Molecular Design for Drug Discovery
Mr Lukas FRIEDRICH
ETH ZURICH, Zurich, Switzerland
Lukas Friedrich studied chemistry at the Swiss Federal Institute of Technology (ETH) in Zurich. He completed his undergraduate studies in 2015, and received a master‘s degree in Chemistry in 2016. Since then he is conducting his PhD studies in the group of Prof. Gisbert Schneider at the Institute of Pharmaceutical Sciences at ETH Zurich. His research interests focus on computational drug design, medicinal chemistry and the application of artificial intelligence in drug discovery.
15:45
OC03 - Targeted Metabolomics Profiling as a Basis for Predictive Models in Multiple Sclerosis Research
Winner of the young medicinal chemist meeting in Russia
Mr Marat KASAKIN
INSTITUTE OF CHEMICAL BIOLOGY AND FUNDAMENTAL MEDICINE, Novosibirsk, Russia
Studied chemistry at the Novosibirsk State University (Russia). Performed diploma thesis on antisense morpholino oligonucleotide analogs under the supervision of Prof. Tatiana Abramova. Since 2012 working at the facility core of mass-spectrometry at the Institute of Chemical Biology and Fundamental Medicine, focusing on pharmacokinetic studies in pre-clinical drug research. Since 2015 cooperates with Novosibirsk State University at the Joint Center for proteomics and metabolomics studies under the supervision of Prof. Vladimir Koval. In 2017 he started the project on multiple sclerosis metabolic profiling. The current position is researcher engineer at the Institute of Chemical Biology and Fundamental Medicine. Research interests focused on biochemistry, metabolomics and proteomics studies of the diseases, data analysis and novel methods of diagnostics.
16:05
Flash poster presentations (0-10)
FP01 - Targeting Basic Defect in Cystic Fibrosis: Discovery and Development of Novel Nanomolar F508-Del CFTR Correctors
Dr Alejandra RODRIGUEZ-GIMENO
ISTITUTO ITALIANO DI TECNOLOGIA, Genova, Italy
FP02 - Buruli Ulcer and The mTOR Pathway: Total Synthesis, Structure-Activity and Target Elucidation Studies of Mycolactones
Prof. Matthias GEHRINGER
UNIVERSITY OF TUEBINGEN, Tuebingen, Germany
FP03 - The Development of New Treatments for Multi-Drug Resistant Tuberculosis
Ms Lisa BARBARO
MONASH UNIVERSITY, Reservoir, Australia
FP04 - Synthesis and Characterisation of Psoralen Derivates as Inhibitors of The β5i Subunit of the Immunoproteasome
Ms Eva Shannon SCHIFFRER
UNIVERSITY OF LJUBLJANA, FACULTY OF PHARMACY, Zirovnica, Slovenia
FP05 - Fragment-Based Approach Applied to The Discovery of Protein-Protein Interaction Stabilisers
Mr Dario VALENTI
TAROS CHEMICALS GMBH & CO. KG, Dortmund, Germany
FP06 - The Use of Irreversible Ligands in the Quest to Obtain the First Ligand-Bound X-Ray Structures of The Adenosine A1 Receptor
Dr Manuela JORG
MONASH UNIVERSITY, Parkville, Australia
FP07 - Inhibitors of Human Sialyltransferases as Novel Anti-Metastatic Agents
Mr Chris DOBIE
UNIVERSITY OF WOLLONGONG, Gwynneville, Australia
FP08 - 3-Oxabicyclo[4.1.0]Heptane: A Bioisostere for Morpholine as a Kinase Hinge Binding Moiety
Mr Declan SUMMERS
GLAXOSMITHKLINE, Stevenage, United Kingdom
FP09 - Development of Small-Molecule Inhibitors of Adipose Triglyceride Lipase (ATGL)
Ms Anna MIGGLAUTSCH
TU GRAZ, Graz, Austria
FP10 - Covalent Fragment-Based Discovery of New Mura Inhibitors
Dr Martina HRAST
FAKULTETA ZA FARMACIJO, Ljubljana, Slovenia
16:25
YMCS competition presentation session II
Session Chair
Dr Kristina GONCHARENKO
SPIROCHEM AG, Basel, Switzerland
16:40
OC04 - The Design and Synthesis of Bromodomain Photoaffinity Probes
Winner of the young medicinal chemist meeting in the United Kingdom
Mr David FALLON
GLAXOSMITHKLINE, Stevenage, United Kingdom
For my undergraduate studies, I graduated top of my class (2015) in Medicinal Chemistry from Trinity College Dublin and was awarded a Trinity gold medal for distinction. During my time as an undergraduate, I spent a year working in GSK Stevenage on the Industrial placement programme in the epigenetics department.1,2 I then returned to Trinity and performed a final year project in organocatalysis and kinetic resolution with Prof. Stephen Connon. After enjoying time in both industry and academia, I decided to get the best of both and joined the GSK/Strathclyde collaborative PhD programme under the supervision of Dr. Jacob Bush and Prof. Nick Tomkinson. Now in my third year, my work involves enhancing current methods of target tractability and engagement by using a photoaffinity labelling approach.
Notable achievements during my PhD:
• Awarded best poster presentation at “SCI Epigenetics 2017” in Eli Lilly (7th Sept 2017).
• Awarded best oral presentation at “11th Biological and Medicinal Chemistry Symposium for Postgraduates” in Cambridge (8th Dec 2017).
• Awarded best oral presentation at “2018 RSC Chemical Biology and Bio-organic Group Postgraduate Symposium” in Leeds (10th May 2018).
• Awarded PECRE funding (to the value of £4700) from the Scottish Funding Council (ScotCHEM) for a 3-month placement with Cellzome in Heidelberg, Germany (12th Mar – 15th Jun 2018).
17:00
OC05 - Gemini-Type Protacs: a Small Molecule-Based Strategy for Self-directed Inactivation of Cereblon
Dr Christian STEINEBACH
UNIVERSITY OF BONN, Bonn, Germany
Christian Steinebach completed his undergraduate studies in Pharmacy (state examination) at the University of Bonn, Germany. In 2015, he became a licensed Pharmacist and got the Carl-Friedrich-Mohr award. He received his MSc in Drug Development in 2016. Since then he is performing his PhD studies in Pharmaceutical Chemistry supervised by Prof. Michael Gütschow at the Pharmaceutical Institute in Bonn. In 2018, he successfully applied for a PhD-related scholarship from the Bonn International Graduate School of Drug Sciences. His scientific work is devoted to the Medicinal Chemistry of Proteolysis Targeting Chimeras (PROTACs), to the design and synthesis of bioactive molecules acting by a new modality of targeted degradation of disease causing proteins, as well as to general questions about the utilization of the ubiquitin-proteasome system.
17:20
OC06 - Investigation of Direct Effect of Psychoactive Compounds on Invertebrate Neurons in Real Time
Winner of the young medicinal chemist meeting in Hungary
Dr Gabor MAASZ
HUNGARIAN ACADEMY OF SCIENCES, Budapest, Hungary
DR. GABOR MAASZ PhD– Research Fellow in Balaton Limnological Institute, Centre for Ecological Research, Hungarian Academy of Sciences
Brief description of the main scopes:
Monitor of organic pollutants (steroids, drug residues) at catchment area of Lake Balaton.
Investigation of adaptation mechanisms to the antropogenic exposure in aquatic test animals.
Liquid chromatography-Mass spectrometer (LC-MS) online system was used to the investigations.
Main profile in keywords: Neurochemistry, Neuropeptides, Proteomics, Mass Spectrometry
Education
2005-2010 University of Pécs, Medical School Pharmacy program-M.Sc.-pharm.doc.
2010-2013 University of Pécs, Medical School,Institute of Biochemistry and Medical
Chemistry,Interdisciplinary Doctoral School – PhD student
2015 Ph.D. University of Pécs, Interdisciplinary Doctoral School (Title of Ph.D. dissertation: Investigation of effect of PACAP to the central nervous sytem by mass spectrometry technics)
Professional experience
2013-2014 University of Pécs, Medical School,Institute of Biochemistry and Medical Chemistry,Interdisciplinary Doctoral School – assistant professor
2014-2017 Hungarian Academy of Sciences, Office for Research Groups, Adaptive Neuroetology research Group– research fellow
2017- Hungarian Academy of Sciences, Centre for Ecological Research, Balaton Limnological Institute – research fellow
17:40
OC07 - Hydrogen peroxide sensitive prodrugs of methotrexate and aminopterin for the treatment of rheumatoid arthritis
Winner of the young medicinal chemist meeting in Denmark
Dr Jorge PEIRO CADAHIA
NUEVOLUTION A/S, Copenhagen, Denmark
Dr. Jorge Peiró Cadahía is a Research Scientist at the Scandinavian biopharmaceutical company Nuevolution A/S. The company focuses on the development of drug treatments for human diseases within oncology and chronic inflammatory diseases using their DNA encoded libraries technology. Jorge is part of the research group working on the discovery of new Bromodomain and Extra-Terminal (BET) protein inhibitors for the treatment of inflammatory conditions, a project in the lead optimization stage.
In 2012, he obtained his B.Sc. degree from the Universidad Autónoma de Madrid (Madrid, Spain) and in 2014 his M.Sc. degree from the Technical University of Denmark (Copenhagen, Denmark). He obtained his Ph.D. degree in 2017 from the same university, where he worked on the development of prodrugs for the treatment inflammatory diseases and cancer, under the supervision of Prof. Mads H. Clausen. His work has been recently published in the Journal of Medicinal Chemistry and the European Journal of Medicinal Chemistry. Jorge has also carried out a research project on the discovery and development of novel Pd-catalyzed C‒H activation methodologies under the supervision of Prof. Matthew J. Gaunt at the University of Cambridge.
18:00
Flash poster presentations (10-20)
FP11 - Rational Design of Optimized Allosteric Effectors of Cathepsins K and S Based on Succinimide-Glycinate Scaffold
Ms Tjasa GORICAN
UNIVERSITY OF LJUBLJANA, Ljubljana, Slovenia
FP12 - Covalent Inhibition with Terminal Alkyne As ‘Inert’ Electrophile
Mrs Elma MONS
LEIDEN UNIVERSITY MEDICAL CENTER, Leiden, The Netherlands
FP13 - Exploration of Chemical Space of Two Classes of INHA Inhibitors
Dr Izidor SOSIC
UNIVERSITY OF LJUBLJANA, Ljubljana, Slovenia
FP14 - Late-Stage Functionalization of Peptides: Novel Site-Selective Modification & Bioconjugation
Dr Anaïs NOISIER
ASTRAZENECA, Mölndal, Sweden
FP15 - Identification of A GSK-3β/CK-1δ Inhibitor: Dual Target and Dual Mechanisms of Action as Possible Strategy for The Treatment of Parkinson’s Disease.
Prof. Stephanie FEDERICO
UNIVERSITY OF TRIESTE, Trieste, Italy
FP16 - Discovery of Benzothiazole-Based DNA Gyrase and Topoisomerase IV Inhibitors with Broad Spectrum Antibacterial Activity
Ms Martina DURCIK
UNIVERSITY OF LJUBLJANA, Ljubljana, Slovenia
FP17 - Development of Peptides as Therapeutics for Pharmacological Intervention in Vital Protein Cascades
Dr Christina LAMERS
UNIVERSITY OF BASEL, Leipzig, Germany
FP18 - Deep Learning Applications in The Design and Identification of Antibacterial Compounds
Dr Marko JUKIC
FAKULTETA ZA FARMACIJO, UNIVERSITY OF LJUBLJANA, Ljubljana, Slovenia
FP19 - The Design and Synthesis of Novel Inhibitors of the Notch Activation Complex Kinase for Notch Mediated Tumorigenesis
Ms Tanya KELLEY
UNIVERSITY OF MIAMI, miami, United States
18:20
Poster presentation session 1 (Odd numbers) & Networking drink
20:00
20:15
Optional Networking Event (until 21:30)